Imetelstat shows promise for LR-MDS patients post other therapies
FOSTER CITY, Calif. - Geron Corporation , a biopharmaceutical company with a market capitalization of $2.4 billion and an impressive 92% stock return over the past year, today revealed new data from the IMerge clinical trial at the 66th American Society of Hematology (ASH) Annual Meeting. The data indicates that imetelstat, a telomerase inhibitor, may be beneficial for patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia, irrespective of their previous treatments.
The pooled analyses from IMerge Phase 2, Phase 3, and the QTc substudy included 226 patients treated with imetelstat. These patients had previously been treated with therapies such as erythropoiesis-stimulating agents (ESAs), luspatercept, lenalidomide, and hypomethylating agents (HMAs). According to InvestingPro data, analysts are forecasting substantial revenue growth of over 310% for the coming year, reflecting the market potential of this treatment. For deeper insights into Geron's growth prospects and 10+ additional ProTips, consider exploring InvestingPro's comprehensive analysis. The findings suggest that imetelstat's clinical activity is consistent with previous results from the IMerge Phase 3 pivotal trial, offering potential benefits even to those who were ESA ineligible or had prior treatments.
Furthermore, patient-reported outcomes from the Phase 3 portion of the IMerge trial indicated sustained improvements in fatigue and maintenance of quality of life and anemia symptoms with imetelstat compared to a placebo.
RYTELO™ (imetelstat) is the first FDA-approved telomerase inhibitor for the treatment of adult patients with LR-MDS with transfusion-dependent anemia who are not responsive to, or eligible for, ESAs. It is administered intravenously every four weeks.
Investors and stakeholders in the biopharmaceutical industry will be monitoring the developments around imetelstat, as it represents a potential advancement in the treatment of LR-MDS and other blood cancers.
In other recent news, Geron Corporation reported a transformative Q3 2024, marked by the successful launch of RYTELO, its first-in-class telomerase inhibitor. The drug, aimed at treating lower-risk myelodysplastic syndromes (MDS), generated $28.2 million in net product revenue, indicating strong market demand. Geron's total net revenues reached $28.3 million, a significant leap from the previous year.
